MSD’s pneumococcal vaccine hits ‘key endpoints’ in Phase III
Phase III trial evaluated use in infants 42-90 days old
Read More
Tag: Vaxneuvance
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
